Table 3:
Adverse events
| Lidocaine | Placebo | |||
|---|---|---|---|---|
| Affected/at Risk (%) | Symptom duration in minutes, median (range) | Affected/at Risk (%) | Symptom duration in minutes, median (range) | |
| Dry mouth | 13/34 (40) | 60 (20 to 85) | 8/33 (24) | 50 (39 to 237) |
| Drowsiness | 9/34 (26) | 94 (50 to 529) | 4/33 (12) | 115 (52 to 675) |
| Perioral numbness | 8/34 (24) | 34 (1 to 75) | 2/33 (6) | 30 (18 to 43) |
| Dysesthesia | 7/34 (21) | 16 (2 to 72) | 1/33 (3) | 10 |
| Dizziness | 6/34 (18) | 52 (31 to 475) | 1/33 (3) | 50 |
| Nausea | 2/34 (6) | 46 (22 to 71) | 0/33 (0) | - |
| Slurred speech | 2/34 (6) | 25 (7 to 43) | 0/33 (0) | - |
| Blurred vision | 1/34 (3) | 59 | 0/33 (0) | - |
| Headache | 1/34 (3) | 325 | 1/33 (3) | 486 |
| Arrhythmia | 0/34 (0) | - | 1/33 (3) | 33 |
| Death | 0/34 (0) | - | 0/34 (0) | - |